Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 2/2016

01.06.2016 | short review

Circulating tumor cells and circulating tumor DNA in colon cancer

Prospects and difficulties in implementation

verfasst von: Mikhail Fedyanin, MD, PhD, Elizaveta Polyanskaya, MD, Sergei Tjulandin, MD, PhD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

It is known that tumor cells have the ability to penetrate into the bloodstream. The identification of such circulating tumor cells (CTC) determines the prognosis in several tumors, including colon cancer. Tumor DNA (ctDNA), which is only a part of the total circulating DNA obtained from the blood of cancer patients, is also further separated from plasma. This separation of the neoplastic derivatives of the primary tumor and metastases (CTC, ctDNA, RNA, proteome) in plasma is called “liquid biopsy.” CTC increasingly represents the pool of tumor cells that can initiate the growth of metastatic lesions, while the ctDNA provides the information about the whole tumor mass. Traditional tissue biopsy gives information based only on one small section of the primary tumor or metastasis, often retrieved before the start of treatment; however, liquid biopsy provides real-time information about the molecular disorders for the whole tumor mass and allows us to estimate the dynamics of the evolutionary tumor changes, the heterogeneity of the disease, and the effect of chemotherapy. With the possibility of obtaining multiple blood samples for analysis during the therapy, in contrast to traditional biopsy, it also allows us to evaluate the mechanisms of resistance to treatment, which in the future will perhaps lead to modification of the treatment in accordance with the detected molecular defects in tumors. Thus, this would facilitate implementing the principles of personalized therapy. In this literature review, we concentrate on liquid biopsy in patients with colon cancer.
Literatur
1.
Zurück zum Zitat Ashworth T. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J. 1869;14:146–149. Ashworth T. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J. 1869;14:146–149.
2.
Zurück zum Zitat Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442–454.CrossRefPubMed Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442–454.CrossRefPubMed
3.
Zurück zum Zitat Miller MC, Doyle GV, Terstappen LW. Significance of circulating tumor cells detected by the CellSearch system in patients with metastatic breast colorectal and prostate cancer. J Oncol. 2010;2010:1–8.CrossRef Miller MC, Doyle GV, Terstappen LW. Significance of circulating tumor cells detected by the CellSearch system in patients with metastatic breast colorectal and prostate cancer. J Oncol. 2010;2010:1–8.CrossRef
4.
Zurück zum Zitat Hiraiwa K, Takeuchi H, Hasegawa H, et al. Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancers. Ann Surg Oncol. 2008;15(11):3092–3100.CrossRefPubMed Hiraiwa K, Takeuchi H, Hasegawa H, et al. Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancers. Ann Surg Oncol. 2008;15(11):3092–3100.CrossRefPubMed
5.
Zurück zum Zitat Molnar B, Ladanyi A, Tanko L, et al. Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin Cancer Res. 2001;7(12):4080–4085.PubMed Molnar B, Ladanyi A, Tanko L, et al. Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin Cancer Res. 2001;7(12):4080–4085.PubMed
6.
Zurück zum Zitat Rahbari NN, Aigner M, Thorlund K, et al. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology. 2010;138(5):1714–1726.CrossRefPubMed Rahbari NN, Aigner M, Thorlund K, et al. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology. 2010;138(5):1714–1726.CrossRefPubMed
7.
Zurück zum Zitat Thorsteinsson M, Soletormos G, Jess P. Low number of detectable circulating tumor cells in non-metastatic colon cancer. Anticancer Res. 2011;31(2):613–617.PubMed Thorsteinsson M, Soletormos G, Jess P. Low number of detectable circulating tumor cells in non-metastatic colon cancer. Anticancer Res. 2011;31(2):613–617.PubMed
8.
Zurück zum Zitat Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(19):3213–3221.CrossRefPubMed Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(19):3213–3221.CrossRefPubMed
9.
Zurück zum Zitat Tol J, Koopman M, Miller MC, et al. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol. 2010;21(5):1006–1012.CrossRefPubMed Tol J, Koopman M, Miller MC, et al. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol. 2010;21(5):1006–1012.CrossRefPubMed
10.
Zurück zum Zitat Sastre J, Maestro ML, Gomez MA, et al. Enumeration circulating tumor cells (CTCs) is a prognostic and predictive factor for progression free survival (PFS) and overall survival in colon cancer patients receiving first-line chemotherapy plus bevacizumab. A TTD Spanish group cooperative study. Ann Oncol. 2010;21(Suppl. 8):viii63–viii77. Sastre J, Maestro ML, Gomez MA, et al. Enumeration circulating tumor cells (CTCs) is a prognostic and predictive factor for progression free survival (PFS) and overall survival in colon cancer patients receiving first-line chemotherapy plus bevacizumab. A TTD Spanish group cooperative study. Ann Oncol. 2010;21(Suppl. 8):viii63–viii77.
11.
Zurück zum Zitat Smerage JB, Barlow WE, Hortobagyi GN, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S050. J Clin Oncol. 2014;32(31):3483–3489.CrossRefPubMedPubMedCentral Smerage JB, Barlow WE, Hortobagyi GN, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S050. J Clin Oncol. 2014;32(31):3483–3489.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Huang MY, Wang HM, Chang HJ, et al. Overexpression of S100B, TM4SF4, and OLFM4 genes is correlated with liver metastasis in Taiwanese colorectal cancer patients. DNA Cell Biol. 2012;31(1):43–49.CrossRefPubMedPubMedCentral Huang MY, Wang HM, Chang HJ, et al. Overexpression of S100B, TM4SF4, and OLFM4 genes is correlated with liver metastasis in Taiwanese colorectal cancer patients. DNA Cell Biol. 2012;31(1):43–49.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24.CrossRefPubMedPubMedCentral Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Mandel PM, Métais P. Les acides nucleiques du plasma sanguine chez l’homme. CR Acad Sci Paris. 1947;142:241–253. Mandel PM, Métais P. Les acides nucleiques du plasma sanguine chez l’homme. CR Acad Sci Paris. 1947;142:241–253.
15.
Zurück zum Zitat Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37:646–650.PubMed Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37:646–650.PubMed
16.
Zurück zum Zitat Hibi K, Robinson CR, Booker S, et al. Molecular detection of genetic alterations in the 505 serum of colorectal cancer patients. Cancer Res. 1998;58:1405–1407.PubMed Hibi K, Robinson CR, Booker S, et al. Molecular detection of genetic alterations in the 505 serum of colorectal cancer patients. Cancer Res. 1998;58:1405–1407.PubMed
17.
Zurück zum Zitat Lecomte T, Ceze N, Dorval E, Laurent-Puig P. Circulating free tumor DNA and colorectal cancer. Gastroenterol Clin Biol. 2010;34:662–681.CrossRefPubMed Lecomte T, Ceze N, Dorval E, Laurent-Puig P. Circulating free tumor DNA and colorectal cancer. Gastroenterol Clin Biol. 2010;34:662–681.CrossRefPubMed
18.
Zurück zum Zitat Sikora A, Zimmermann BG, Rusterholz C, et al. Detection of increased amounts of cell-free fetal DNA with short PCR amplicons. Clin Chem. 2010;56:136–138.CrossRefPubMed Sikora A, Zimmermann BG, Rusterholz C, et al. Detection of increased amounts of cell-free fetal DNA with short PCR amplicons. Clin Chem. 2010;56:136–138.CrossRefPubMed
19.
Zurück zum Zitat Jung K, Fleischhacker M, Rabien A. Cell-free DNA in the blood as a solid tumor biomarker – a critical appraisal of the literature. Clin Chim Acta. 2010;411:1611–1624.CrossRefPubMed Jung K, Fleischhacker M, Rabien A. Cell-free DNA in the blood as a solid tumor biomarker – a critical appraisal of the literature. Clin Chim Acta. 2010;411:1611–1624.CrossRefPubMed
20.
Zurück zum Zitat Danese E, Minicozzi AM, Benati M, et al. Comparison of genetic and epigenetic alterations of primary tumors and matched plasma samples in patients with colorectal cancer. PLoS ONE. 2015;10(5):e0126417 doi:10.1371/journal.pone.0126417.CrossRefPubMedPubMedCentral Danese E, Minicozzi AM, Benati M, et al. Comparison of genetic and epigenetic alterations of primary tumors and matched plasma samples in patients with colorectal cancer. PLoS ONE. 2015;10(5):e0126417 doi:10.1371/journal.pone.0126417.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Kuo YB, Chen JS, Li YS, Chan EC. Comparison of KRAS mutation analysis of primary tumors and matched 2 circulating cell-free DNA in plasmas of patients with colorectal cancer. Clin Chim Acta. 2014;433:284–289.CrossRefPubMed Kuo YB, Chen JS, Li YS, Chan EC. Comparison of KRAS mutation analysis of primary tumors and matched 2 circulating cell-free DNA in plasmas of patients with colorectal cancer. Clin Chim Acta. 2014;433:284–289.CrossRefPubMed
22.
Zurück zum Zitat Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 2015;61(1):112–123.CrossRefPubMed Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 2015;61(1):112–123.CrossRefPubMed
23.
Zurück zum Zitat Spindler KLG, Appelt AL, Pallisgaard N, et al. Cell-free DNA levels in colorectal cancer patients treated with irinotecan, healthy controls, and non-cancer patients with comorbidity. J Clin Oncol. 2014;32(5s):suppl; abstr 3559. Spindler KLG, Appelt AL, Pallisgaard N, et al. Cell-free DNA levels in colorectal cancer patients treated with irinotecan, healthy controls, and non-cancer patients with comorbidity. J Clin Oncol. 2014;32(5s):suppl; abstr 3559.
24.
Zurück zum Zitat Danese E, Montagnana M, Minicozzi AM, et al. Real-time polymerase chain reaction quantification of free DNA in serum of patients with polyps and colorectal cancers. Clin Chem Lab Med. 2010;48(11):1665–1668.CrossRefPubMed Danese E, Montagnana M, Minicozzi AM, et al. Real-time polymerase chain reaction quantification of free DNA in serum of patients with polyps and colorectal cancers. Clin Chem Lab Med. 2010;48(11):1665–1668.CrossRefPubMed
25.
Zurück zum Zitat Tie J, Kinde I, Wang Y, et al. Circulating tumor DNA (ctDNA) as a marker of recurrence risk in stage II colon cancer (CC). J Clin Oncol. 2014;33(suppl 5):abstr 11015. Tie J, Kinde I, Wang Y, et al. Circulating tumor DNA (ctDNA) as a marker of recurrence risk in stage II colon cancer (CC). J Clin Oncol. 2014;33(suppl 5):abstr 11015.
26.
Zurück zum Zitat Mouliere F, Thierry AR. The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients. Expert Opin Biol Ther. 2012;12(Suppl.1):209–215.CrossRef Mouliere F, Thierry AR. The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients. Expert Opin Biol Ther. 2012;12(Suppl.1):209–215.CrossRef
27.
Zurück zum Zitat Tabernero J, Lenz HJ, Siena S, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 2015;: doi:10.1016/S1470-2045(15)00138-2 Tabernero J, Lenz HJ, Siena S, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 2015;: doi:10.1016/S1470-2045(15)00138-2
28.
Zurück zum Zitat Wong ALA, Lim JSJ, Sinha A, et al. Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. J Transl Med. 2015;13:57.CrossRefPubMedPubMedCentral Wong ALA, Lim JSJ, Sinha A, et al. Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. J Transl Med. 2015;13:57.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Teufel M, Kalmus J, Rutstein M. et al. Analysis of biomarkers in circulating tumor DNA from the phase 3 CONCUR study of regorafenib in Asian patients with metastatic colorectal cancer (mCRC): Correlation with clinical outcome ECOO2015 congress. vol abctract#2013. 2015. Teufel M, Kalmus J, Rutstein M. et al. Analysis of biomarkers in circulating tumor DNA from the phase 3 CONCUR study of regorafenib in Asian patients with metastatic colorectal cancer (mCRC): Correlation with clinical outcome ECOO2015 congress. vol abctract#2013. 2015.
30.
Zurück zum Zitat Andersen RF, Spindler KL, Brandslund I, et al. Improved sensitivity of circulating tumor DNA measurement using short PCR amplicons. Clin Chim Acta. 2015;439:97–101.CrossRefPubMed Andersen RF, Spindler KL, Brandslund I, et al. Improved sensitivity of circulating tumor DNA measurement using short PCR amplicons. Clin Chim Acta. 2015;439:97–101.CrossRefPubMed
31.
Zurück zum Zitat Morelli MP, Overman MJ, Sanchez EV, et al. Frequency of concurrent gene mutations and copy number alterations in circulating cell-free DNA (cfDNA) from refractory metastatic CRC patients. J Clin Oncol. 2014;32(5s):abstr 11117. Morelli MP, Overman MJ, Sanchez EV, et al. Frequency of concurrent gene mutations and copy number alterations in circulating cell-free DNA (cfDNA) from refractory metastatic CRC patients. J Clin Oncol. 2014;32(5s):abstr 11117.
32.
Zurück zum Zitat Marziali A, Vysotskaia V, Wiggin M, et al. Circulating tumor DNA as a highly specific diagnostic marker for colorectal cancer. J Clin Oncol. 2014;32(suppl):abstr e22126. Marziali A, Vysotskaia V, Wiggin M, et al. Circulating tumor DNA as a highly specific diagnostic marker for colorectal cancer. J Clin Oncol. 2014;32(suppl):abstr e22126.
33.
Zurück zum Zitat Sefrioui D, Vasseur N, Sesboüé R, et al. Plasma cell-free DNA and fraction of circulating KRAS mutations as prognostic in patients with metastatic colorectal cancer. J Clin Oncol. 2014;32(suppl 3):abstr 490. Sefrioui D, Vasseur N, Sesboüé R, et al. Plasma cell-free DNA and fraction of circulating KRAS mutations as prognostic in patients with metastatic colorectal cancer. J Clin Oncol. 2014;32(suppl 3):abstr 490.
34.
Zurück zum Zitat Liu F, Li C, Zhao J. et al. Detection of KRAS mutations in plasma from patients with metastatic colorectal cancer by the next-generation sequencing ECOO2015 congress. vol abctract#2185. 2015. Liu F, Li C, Zhao J. et al. Detection of KRAS mutations in plasma from patients with metastatic colorectal cancer by the next-generation sequencing ECOO2015 congress. vol abctract#2185. 2015.
35.
Zurück zum Zitat Jones F, Edelstein D, Wichner K. et al. Concordance of RAS mutation status in metastatic CRC patients by comparison of results from circulating tumor DNA and tissue-based RAS testing ECOO2015 congress. vol abctract#2012. 2015. Jones F, Edelstein D, Wichner K. et al. Concordance of RAS mutation status in metastatic CRC patients by comparison of results from circulating tumor DNA and tissue-based RAS testing ECOO2015 congress. vol abctract#2012. 2015.
36.
Zurück zum Zitat Yamada T, Kan H, Matsumoto S, et al. Liquid biopsy detection of KRAS and BRAF mutations may be useful as a prognostic or predictive marker. Ann Oncol. 2014;25(suppl_4):iv58–iv84. doi:10.1093/annonc/mdu326. Yamada T, Kan H, Matsumoto S, et al. Liquid biopsy detection of KRAS and BRAF mutations may be useful as a prognostic or predictive marker. Ann Oncol. 2014;25(suppl_4):iv58–iv84. doi:10.1093/annonc/mdu326.
37.
Zurück zum Zitat Poole JC, Vibat CRT, Benesova L, et al. Highly sensitive quantitative detection of circulating tumor DNA in urine and plasma from advanced colorectal cancer patients in aid of early diagnosis of clinically relevant KRAS mutations. J Clin Oncol. 2015;33(suppl 3):abstr 654. Poole JC, Vibat CRT, Benesova L, et al. Highly sensitive quantitative detection of circulating tumor DNA in urine and plasma from advanced colorectal cancer patients in aid of early diagnosis of clinically relevant KRAS mutations. J Clin Oncol. 2015;33(suppl 3):abstr 654.
38.
Zurück zum Zitat Kopreski MS, Benko FA, Borys DJ, et al. Somatic mutation screening: identification of individuals harboring K‑ras mutations with the use of plasma DNA. J Natl Cancer Inst. 2000;92:918–923.CrossRefPubMed Kopreski MS, Benko FA, Borys DJ, et al. Somatic mutation screening: identification of individuals harboring K‑ras mutations with the use of plasma DNA. J Natl Cancer Inst. 2000;92:918–923.CrossRefPubMed
39.
40.
Zurück zum Zitat Diaz LA Jr, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486:537–540.PubMedPubMedCentral Diaz LA Jr, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486:537–540.PubMedPubMedCentral
41.
Zurück zum Zitat Mohan S, Heitzer E, Ulz P, et al. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet. 2014;10:e1004271.CrossRefPubMedPubMedCentral Mohan S, Heitzer E, Ulz P, et al. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet. 2014;10:e1004271.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Siravegna G, Mussolin B, Buscarino M, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21:795–801.CrossRefPubMed Siravegna G, Mussolin B, Buscarino M, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21:795–801.CrossRefPubMed
Metadaten
Titel
Circulating tumor cells and circulating tumor DNA in colon cancer
Prospects and difficulties in implementation
verfasst von
Mikhail Fedyanin, MD, PhD
Elizaveta Polyanskaya, MD
Sergei Tjulandin, MD, PhD
Publikationsdatum
01.06.2016
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2016
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-016-0263-7

Weitere Artikel der Ausgabe 2/2016

memo - Magazine of European Medical Oncology 2/2016 Zur Ausgabe